Drug intelligence / Profile preview

TLX-047

Development stage: Unknown
Lead developer: Easywell Biomedicals
Modality: Small Molecules

Overview

TLX-047 is a small molecule anti-inflammatory drug developed by Tulex Pharmaceuticals, the U.S. subsidiary of Easywell Biomedical. It is intended for the treatment of various inflammatory conditions. While the specific active ingredient and biological target remain undisclosed in public records, the drug achieved a significant regulatory milestone by receiving FDA approval notification in June 2025. The therapeutic is part of Easywell Biomedical's broader pharmaceutical pipeline focused on addressing unmet needs in inflammatory and neurological disorders.

Beyond the preview

Go deeper on TLX-047.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLX-047.

Explore the full profile